|
Match
|
Document |
Document Title |
|
|
6902735 |
Antibodies to human IL-17F and other CTLA-8-related proteins
Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their...
|
|
|
6902734 |
Anti-IL-12 antibodies and compositions thereof
The present invention relates to at least one anti-IL-12 antibody, including isolated nucleic acids that encode at least one anti-IL-12 antibody, IL-12, vectors, host cells, transgenic animals or...
|
|
|
6887468 |
Antibody kits for selectively inhibiting VEGF
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet...
|
|
|
6884417 |
Monoclonal antibodies immunoreactive with lipopolysaccharide binding protein (LBP) and methods of their use
The present invention concerns a method of treating LBP-mediated LPS-induced myeloid cell activation comprising administering a therapeutically effective amount of an anti-LBP monoclonal antibody...
|
|
|
6869605 |
BAFF, inhibitors thereof and their use in the modulation of B-cell response
The invention provides methods for treating or preventing disorders associated with expression of BAFF comprising BAFF and fragments thereof, antibodies, agonists and antagonists.
|
|
|
6863890 |
Treatment of AIDS with antibodies to gamma interferon, alpha interferon and TNF-alpha
The present disclosure concerns the treatment of a patient with autoimmune disease, including AIDS, by neutralizing, removing or inhibiting different types of interferons, tumor necrosis factor,...
|
|
|
6841153 |
Prevention of adhesions
Methods for the prevention of adhesion formation involve the administration of therapeutic formulations to a patient which include antibodies to TIMP-1 or TIMP-1 antisense oligonucleotides. The...
|
|
|
6833132 |
Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity
Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other...
|
|
|
6814966 |
Methods for treating glaucoma
This invention provides a method for treating a subject with glaucoma comprising the steps of administrating a compound or composition which antagonize, inhibits, inactivates, reduce, suppresses,...
|
|
|
6814967 |
Antibodies to cortistatin: neuropeptides, compositions and methods
The present invention relates generally to nucleic acids encoding a novel neuropeptide designated cortistatin. The cortistatin nucleic acids, proteins and polypeptides thereof along with...
|
|
|
6811780 |
Methods of using cytokine antagonists to treat HIV infection and AIDS
The invention is methods of using cytokine antagonists to treat HIV. In particular, the invention is methods of treating HIV using L-4 and IL-13 cytokine antagonists, including cytokine traps and...
|
|
|
6800649 |
Method for inhibiting c-jun expression using JAK-3 inhibitors
The invention provides a method for inhibiting c-jun activation in mammalian or avian cells comprising contacting the cells with a substance that inhibits the activity of Janus family kinase 3...
|
|
|
6793920 |
Antithrombotic agent and anti-von willebrand factor monoclonal antibody
A monoclonal antibody, which has reactivity with human von Willebrand factor, which has action to inhibit RIPA (ristocetin-induced platelet aggregation), BIPA (botrocetin-induced platelet...
|
|
|
6770279 |
TNFα antagonists and cyclosporin in therapy of rheumatoid arthritis
A method for treating rheumatoid arthritis using a TNFα antagonist in combination with cyclosporin or analog thereof is disclosed.
|
|
|
6761889 |
Anti-IgE antibodies
The present invention relates to a method for adjusting the affinity of a polypeptide to a target molecule by a combination of steps, including: (1) the identification of aspartyl residues which...
|
|
|
6733997 |
Isolated nucleic acids encoding a secretory signal for expression and secretion of heterologous recombinant proteins
A universal secretory signal originally derived from a piscine vitellogenin (Vtg) gene is inserted into various expression vectors for driving the secretion of the recombinant protein into the...
|
|
|
6719972 |
Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies
Isolated ligands which bind a molecule expressed on the surface of T cells and induce antigen specific apoptosis in activated T cells are disclosed. Preferably, the T cell surface molecule is CTLA4...
|
|
|
6713610 |
Human antibodies derived from immunized xenomice
Fully human antibodies against a specific antigen can be prepared by administering the antigen to a transgenic animal which has been modified to produce such antibodies in response to antigenic...
|
|
|
6713058 |
Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
The invention provides methods and compositions for alleviating the symptoms of neuropathic conditions with a pharmaceutical composition including an effective amount of anti-glutamic acid...
|
|
|
6709652 |
Pretargeting methods and compounds
Methods, compounds, compositions and kits that relate to pretargeted delivery of diagnostic and therapeutic agents are disclosed. In particular, methods for radiometal labeling of biotin and for...
|
|
|
6703020 |
Antibody conjugate methods for selectively inhibiting VEGF
Disclosed are antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet...
|
|
|
6699973 |
Antibodies to peptides that target GIT receptors and related methods
The invention provides an antibody or antibody fragment specific to a domain of a GIT targeting agent, such as a polyclonal antibody, monoclonal antibody, chimeric antibody, single chain antibody,...
|
|
|
6692742 |
Remedies for myeloma to be used together with nitrogen mustard antitumor agents
A therapeutic agent for myeloma comprising a combined use of a nitrogen mustard anticancer agent and anti-IL-6 receptor antibody. Thus, a therapeutic agent for myeloma comprising anti-IL-6 receptor...
|
|
|
6692740 |
ACPL antibodies
The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides,...
|
|
|
6689744 |
Notch receptor agonists and uses
The present invention is directed to methods of alleviating prostate disorders by activation of the Notch1 receptor. Also provided herein are methods for detecting and diagnosing prostate...
|
|
|
6673344 |
Antibodies to human CKβ-10/MCP-4
Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods...
|
|
|
6673341 |
Methods of inhibiting proliferative diseases by inhibiting TGF-β-mediated angiogenesis
Disclosed are methods of inhibiting proliferative diseases characterized by TGF-β-mediated angiogenesis.
|
|
|
6663865 |
Tumor necrosis factor antagonists and their use in endometriosis
Tumor necrosis factor antagonists are administered in therapeutically effective doses to treat and/or prevent endometriosis. The antagonists of this invention typically are selected from among...
|
|
|
6656466 |
Human tumor necrosis factor—immunoglobulin(TNFR1-IgG1) chimera composition
The present invention relates to novel process for the preparation of glycoproteins by mammalian cell culture wherein the sialic acid content of the glycoprotein produced is controlled over a broad...
|
|
|
6645493 |
Composition containing anti-MIF antibody
The present invention relates to compositions and methods for inhibiting the release and/or biological activity of migration inhibitory factor (MIF). In particular, the invention relates to the...
|
|
|
6641810 |
Methods of using geldanamycin and FK506 to treat peripheral nerve damage
FK506 and geldanamycin promote nerve regeneration by a common mechanism that involves the binding of these compounds to polypeptide components of steroid receptor complexes other than the steroid...
|
|
|
6635251 |
Eotaxin-specific antibodies
A chemoattractant protein called “eotaxin” is capable of attracting eosinophils and of inducing eosinophil accumulation and/or activation in vitro and in vivo. Various types of agents that...
|
|
|
6635249 |
Methods for treating congestive heart failure
The invention features methods of treating or preventing congestive heart failure by administering a polypeptide containing an epidermal growth factor-like domain encoded by a neuregulin gene.
|
|
|
6635250 |
Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
The present invention relates to pharmaceutical compositions for the treatment of spinal disorders caused by the liberation of TNF-α comprising an effective amount of a TNF-α inhibitor, as well...
|
|
|
6627195 |
Binding agents to CD23
The present invention relates to agents that bind CD23 and that can be used in the treatment of inflammatory, autoimmune or allergic diseases.
|
|
|
6623738 |
Semaphorin receptors
The invention provides methods and compositions relating to two classes of semaphorin receptors, SR1 and SR2. The polypeptides may be produced recombinantly from transformed host cells from the...
|
|
|
6616926 |
Methods of modulating lipid metabolism and storage
Anti-hedgehog antibodies directed at blocking the binding of hedgehog to its receptor patched-1, will impair lipid metabolism and storage. This invention presents methods for the treatment of a...
|
|
|
6610286 |
Method for treating inflammation using soluble receptors to interleukin-20
A method for treating IL-20 induced inflammation. An antagonist to IL-20 is administered to treat inflammation and associated diseases. The antagonist can be an antibody that binds to IL-20 or its...
|
|
|
6605277 |
Conformation-specific anti-von Willebrand factor antibodies
The present invention is directed to antibodies and antibody fragments that bind specifically to the active conformation of human von Willebrand factor. Most preferred are recombinantly produced...
|
|
|
6605278 |
Uses of trank, a novel secretory cytokine
The present invention provides methods for the therapeutic application of TRANK, a novel cytokine. TRANK is secreted by cells and activates NF-κB, c-Jun N-terminal kinase (JNK) and downstream gene...
|
|
|
6596848 |
Antibodies to NIMA interacting proteins
A novel class of NIMA interacting proteins (PIN), exemplified by Pin1, is provided. Pin1 induces a G2 arrest and delays NIMA-induced mitosis when overexpressed, and triggers mitotic arrest and DNA...
|
|
|
6579688 |
Stabilizing diluent for polypeptides and antigens
Compositions for stabilizing polypeptides or antigens are described. These compositions are useful for stabilizing polypeptides or antigens stored in aqueous formulations. Such formulations can be...
|
|
|
6562342 |
Preventives/remedies for inflammatory intestinal disease
Preventives/remedies for at least one disease selected from the group consisting of inflammatory intestinal disease, ischemic colitis and idiopathic inflammatory intestinal disease induced by...
|
|
|
6555110 |
Microencapsulated compounds and method of preparing same
Compositions useful in treating immune modulated disease comprising an anticytokine antibody or immune active drug capable of modifying cytokine activity or modulating the immune system...
|
|
|
6555320 |
Methods and materials for evaluating rheumatoid arthritis
The invention provides methods and materials for diagnosing a rheumatoid arthritis condition in a patient. Specifically, the invention provides methods and materials for classifying a rheumatoid...
|
|
|
6545128 |
Anti-bax inhibitor protein antibodies
The present invention provides substantially purified nucleic acid molecules encoding Bax inhibitor protein-1 (BI-1; SEQ ID NO: 1) or Bax inhibitor protein-2 (BI-2; SEQ ID NO: 4), nucleic acid...
|
|
|
6534058 |
Anti-C5 monoclonal antibodies
The invention relates to C5 inhibitors, which inhibit type II endothelial cell activation, wherein the inhibition is manifested by the suppression of E-selectin. These inhibitors are useful in...
|
|
|
6528055 |
Methods of administering antibodies that specifically bind ACT-4-L-h-1 ligand
The invention provides ligands and fragments thereof to a receptor on the surface of activated CD4 + T-cells. An exemplary ligand is designated ACT-4-L-h-1. Preferred fragments include purified...
|
|
|
6528269 |
Immunological agents specific for prion protein (PRP)
The present invention is directed to a panel of monoclonal antibodies (Mabs) specific for murine prion protein PrP c . These Mabs can be applied to immunoblotting, cell surface immunofluorescent...
|
|
|
6521227 |
Polynucleotides encoding prostatic growth factor and process for producing prostatic growth factor polypeptides
The present invention relates to human PGF polypeptides, DNA (RNA) encoding such polypeptides, and antibodies specifically binding such polypeptides. Also provided are procedures for producing such...
|